Search For "dgci"
DCGI likely to approve phase 3 trial data of Covaxin on Tuesday
Updated : 1 year, 7 months ago IST
New Delhi [India], June 22 (ANI): The Drugs Controller General of India (DCGI) is likely to approve Phase III trial data of Covaxin on Tuesday, sources said.
Read More
DGCI approves emergency use of Zydus's Virafin in treating moderate COVID-
Updated : 1 year, 9 months ago IST
New Delhi [India], April 23 (ANI): Zydus Cadila received emergency use approval from the Drugs Controller General of India (DGCI) on Friday for the use of 'Virafin', Pegylated Interferon alpha-2b (PegIFN) in treating moderate COVID-19 infection in adults.
Read More
Zydus' Virafin gets emergency use approval for treating moderate COVID-19
Updated : 1 year, 9 months ago IST
New Delhi [India], April 23 (ANI): The Drugs Controller General of India (DGCI) has approved emergency use for Zydus Cadila's Pegylated Interferon alpha-2b, 'Virafin' for treating moderate COVID-19 infection in adults.
Read More
Shortage of Remdesivir doses in K'taka hospitals, DGCI to soon provide sup
Updated : 1 year, 9 months ago IST
Bengaluru (Karnataka) [India], April 14 (ANI): Private Hospitals and Nursing Homes Association's (PHANA) executive committee member Dr Rajashekar on Wednesday admitted that there was a shortage of Remdesivir doses for COVID-19 treatment and that the Drug Controller General of India (DGCI) ha
Read More
Zydus Cadila seeks DCGI nod for using its hepatitis drug for COVID-19 trea
Updated : 1 year, 10 months ago IST
New Delhi (India) [India], April 5 (ANI): Pharmaceutical Company Zydus Cadila on Monday informed that it has sought approval of the Drugs Controller General of India (DGCI) for using its hepatitis drug for the treatment of coronavirus.
Read More
DGCI arrests 215 people in fake invoice cases in 2 months
Updated : 2 years ago IST
New Delhi [India], January 10 (ANI): As many as 215 people have been arrested in the last two months by the Directorate General of GST Intelligence (DGGI) and the CGST Commissionerates in their concerted drive across the country against GST fake invoice frauds.
Read More
Second dose of Covishield should be administered between four to six weeks
Updated : 2 years, 1 month ago IST
New Delhi [India], January 4 (ANI): In its permission to Serum Institute of India for "manufacture for sale or distribution" of COVID-19 vaccine 'Covishield', the DGCI has said that the second dose should be administered between four to six weeks after the first dose and also noted that the
Read More
Current claims over Covishield false, vaccine to be commercialised only af
Updated : 2 years, 5 months ago IST
Pune (Maharashtra) [India], Aug 23 (ANI): The current claims over the Coronavirus vaccine, Covishield, are completely false and it will be commercialised when trials prove successful and regulatory approvals are in place, said Serum Institute of India (SII) on Sunday.
Read More
DGCI nod for Apheresis machine to extract blood plasma in Goa
Updated : 2 years, 6 months ago IST
Panaji (Goa) [India], Aug 4 (ANI): Goa has made a new breakthrough in its plasma therapy for critically ill COVID-19 patients after Drugs Controller General of India (DGCI) gave its approval for using Apheresis machine to extract blood plasma, said Health Minister Vishwajit P Rane.
Read More
COVID-19: Health ministry decides not to put Itolizumab in national treatm
Updated : 2 years, 6 months ago IST
New Delhi, July 26 (ANI): Even as the Drugs Controller General of India (DCGI) has given permission to Itolizumab drug for restricted emergency use on moderate to severe COVID-19 patients, the Union Health Ministry has decided not to include the drug in the national treatment protocol for co
Read More
DCGI gives market approval for Pneumococcal Polysaccharide Conjugate Vacci
Updated : 2 years, 6 months ago IST
New Delhi [India], July 15 (ANI): The Drug Controller General of India (DCGI) has given approval to the first fully indigenously developed Pneumococcal Polysaccharide Conjugate Vaccine.
Read More
DCGI gives nod to Mylan labs to manufacture remdesivir for 'restricted eme
Updated : 2 years, 7 months ago IST
New Delhi [India], July 2 (ANI): The Drug Controller General of India (DCGI) has granted permission to Mylan laboratories to manufacture and market the anti-viral drug remdesivir for 'restricted emergency use' on hospitalised COVID-19 patients, a senior government official said on Thursday.
Read More